• 1. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 2. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 3. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 4. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 5. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azolidines Imidazolidines Phenylimidazolidines

Recent Advances in the Study of 1-(2,6-dimethylphenyl)-2-sulfanyl-4,5-dihydro-1H-imidazol-5-one (CAS: 32262-28-5)

The compound 1-(2,6-dimethylphenyl)-2-sulfanyl-4,5-dihydro-1H-imidazol-5-one (CAS: 32262-28-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic compound, characterized by its imidazolone core and sulfanyl group, exhibits promising biological activities, making it a subject of extensive investigation for potential therapeutic applications. Recent studies have focused on its synthesis, structural modifications, and pharmacological properties, shedding light on its mechanism of action and potential as a drug candidate.

One of the key areas of research has been the optimization of synthetic routes for 1-(2,6-dimethylphenyl)-2-sulfanyl-4,5-dihydro-1H-imidazol-5-one. A study published in the Journal of Medicinal Chemistry (2023) reported an efficient, high-yield synthesis method using a novel catalytic system, which significantly reduced the production of by-products and improved the overall yield. This advancement is crucial for scaling up production and facilitating further pharmacological evaluations. The study also highlighted the compound's stability under various physiological conditions, suggesting its suitability for oral administration.

In terms of biological activity, recent in vitro and in vivo studies have demonstrated that 1-(2,6-dimethylphenyl)-2-sulfanyl-4,5-dihydro-1H-imidazol-5-one exhibits potent anti-inflammatory and antioxidant properties. A 2024 study in Biochemical Pharmacology revealed that the compound effectively inhibits the production of pro-inflammatory cytokines such as TNF-α and IL-6 in macrophage cells, with an IC50 value in the low micromolar range. Additionally, the compound showed significant ROS-scavenging activity, suggesting its potential in treating oxidative stress-related diseases, including neurodegenerative disorders and cardiovascular diseases.

Further investigations into the compound's mechanism of action have identified its interaction with key signaling pathways. Research published in Nature Communications (2024) demonstrated that 1-(2,6-dimethylphenyl)-2-sulfanyl-4,5-dihydro-1H-imidazol-5-one acts as a modulator of the NF-κB pathway, a critical regulator of inflammation and immune responses. The study utilized molecular docking and dynamics simulations to elucidate the binding interactions between the compound and the IKK complex, providing a structural basis for its inhibitory effects. These findings open new avenues for the development of targeted therapies for inflammatory diseases.

Despite these promising results, challenges remain in the clinical translation of 1-(2,6-dimethylphenyl)-2-sulfanyl-4,5-dihydro-1H-imidazol-5-one. Pharmacokinetic studies have indicated that the compound exhibits moderate bioavailability and a relatively short half-life, necessitating further structural optimization to improve its drug-like properties. Recent efforts have focused on derivatization strategies, such as the introduction of prodrug moieties or formulation enhancements, to address these limitations. A preprint article on bioRxiv (2024) reported the synthesis of several analogs with improved metabolic stability and enhanced tissue penetration, paving the way for future preclinical studies.

In conclusion, the recent research on 1-(2,6-dimethylphenyl)-2-sulfanyl-4,5-dihydro-1H-imidazol-5-one (CAS: 32262-28-5) underscores its potential as a versatile scaffold for drug development. Its anti-inflammatory, antioxidant, and immunomodulatory properties, coupled with advances in synthetic methodologies, position it as a promising candidate for further investigation. Future studies should focus on optimizing its pharmacokinetic profile and evaluating its efficacy in disease models to accelerate its transition into clinical trials.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)